Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Thiomyristoyl (TM) is a potent and selective inhibitor of SIRT2 with IC50 values of 0.028, 98, >200, and >200 μM for SIRT2, SIRT1, SIRT3, and SIRT5-7, respectively.1 It inhibits acetyl-H3K9 peptide and NAD binding to SIRT2 and promotes c-Myc degradation in a dose-dependent manner. TM exhibits selective cytotoxicity with IC50 values ranging from 8.4-36.8 and >50 μM for cancerous and non-cancerous cell lines, respectively. It decreases α-tubulin acetylation, a marker of SIRT2 activity, in a dose-dependent manner in MDA-MB-231 breast cancer cells while having no effect on the SIRT1 target p53. Intratumor administration of TM decreases tumor volume and increases areas of necrosis in an MDA-MB-231 mouse breast cancer xenograft model. TM also increases tumor-free survival time in a MMTV-PyMT mouse mammary tumor model.
WARNING This product is not for human or veterinary use.
1. A SIRT2-